Monday May 18, 2015 0 comments
FORT COLLINS -- KromaTiD, a bioscience company dedicated to creating new products for genetic disease research, mutation detection and chromosome analysis, today announced an agreement with Tokyo Future Style for distribution of its proprietary dGH and Pinpoint FISH products and services throughout Japan.
“We are excited to be working with KromaTiD because we believe that their novel genomic technology will be attractive to our customers and the Japanese market," said Takashi Endo, Tokyo Future Style president and CEO.
“KromaTiD’s dGh and Pinpont FISH technologies will offer our customers clear advantages in the fields of gene target discovery and mutation validation with great potential for clinical applications.”
KriomaTiD said its genomic assays are the only imaging assays capable of determining DNA sequence, location and orientation data in a single test.
"Tokyo Future Style has a very focused approach to the Japanese market that we feel makes them a great fit for selling our products and services,” said Alex Vodenlich, KromaTiD’s CEO.